Cerebral Small Vessel Disease and Functional Outcome Prediction After Intracerebral Hemorrhage.

Hostettler, Isabel C; Schwarz, Ghil; Ambler, Gareth; Wilson, Duncan; Banerjee, Gargi; Seiffge, David J; Shakeshaft, Clare; Lunawat, Surabhika; Cohen, Hannah; Yousry, Tarek A; Al-Shahi Salman, Rustam; Lip, Gregory Y H; Brown, Martin M; Muir, Keith W; Houlden, Henry; Jäger, Hans Rolf; Werring, David J (2021). Cerebral Small Vessel Disease and Functional Outcome Prediction After Intracerebral Hemorrhage. Neurology, 96(15), e1954-e1965. American Academy of Neurology 10.1212/WNL.0000000000011746

[img]
Preview
Text
Hostettler__2021__Cerebral_Small_Vessels_Disease.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (3MB) | Preview
[img] Text
e1954.full.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (357kB)

OBJECTIVE

To determine whether CT-based cerebral small vessel disease (SVD) biomarkers are associated with 6-month functional outcome after intracerebral hemorrhage (ICH) and whether these biomarkers improve the performance of the preexisting ICH prediction score.

METHODS

We included 864 patients with acute ICH from a multicenter, hospital-based prospective cohort study. We evaluated CT-based SVD biomarkers (white matter hypodensities [WMH], lacunes, brain atrophy, and a composite SVD burden score) and their associations with poor 6-month functional outcome (modified Rankin Scale score >2). The area under the receiver operating characteristic curve (AUROC) and Hosmer-Lemeshow test were used to assess discrimination and calibration of the ICH score with and without SVD biomarkers.

RESULTS

In multivariable models (adjusted for ICH score components), WMH presence (odds ratio [OR] 1.52, 95% confidence interval [CI] 1.12-2.06), cortical atrophy presence (OR 1.80, 95% CI 1.19-2.73), deep atrophy presence (OR 1.66, 95% CI 1.17-2.34), and severe atrophy (either deep or cortical) (OR 1.94, 95% CI 1.36-2.74) were independently associated with poor functional outcome. For the revised ICH score, the AUROC was 0.71 (95% CI 0.68-0.74). Adding SVD markers did not significantly improve ICH score discrimination; for the best model (adding severe atrophy), the AUROC was 0.73 (95% CI 0.69-0.76). These results were confirmed when lobar and nonlobar ICH were considered separately.

CONCLUSIONS

The ICH score has acceptable discrimination for predicting 6-month functional outcome after ICH. CT biomarkers of SVD are associated with functional outcome, but adding them does not significantly improve ICH score discrimination.

TRIAL REGISTRATION INFORMATION

ClinicalTrials.gov Identifier: NCT02513316.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology

UniBE Contributor:

Seiffge, David Julian

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1526-632X

Publisher:

American Academy of Neurology

Language:

English

Submitter:

Chantal Kottler

Date Deposited:

12 Jul 2021 16:29

Last Modified:

05 Dec 2022 15:51

Publisher DOI:

10.1212/WNL.0000000000011746

PubMed ID:

33627495

BORIS DOI:

10.48350/157361

URI:

https://boris.unibe.ch/id/eprint/157361

Actions (login required)

Edit item Edit item
Provide Feedback